Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 5.1% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company specializing in CRISPR/Cas9-based therapeutics. The stock saw a notable decrease in value.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 5.1% on Jun 5, 2025 13:45

• Beam Therapeutics' gene-editing therapy for sickle cell disease gaining orphan drug status from the FDA resulted in a surge in BEAM stock.
• Despite Wall Street analysts projecting a potential 398.3% upside for Intellia Therapeutics, the stock still experienced a bearish movement.
• Intellia's stock decline could be linked to a patient in its phase III study encountering adverse events, which impacted the company's gene therapy candidate and investor sentiment.
• The gene-editing sector's competition, notably with CRISPR advancing its in vivo pipeline, contributes to the intricate market dynamics affecting Intellia's stock performance.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.

https://www.zacks.com/stock/news/2484541/beam-up-on-fdas-orphan-drug-status-for-gene-editing-therapy

How Much Upside is Left in Intellia Therapeutics ( NTLA ) ? Wall Street Analysts Think 398.31%

The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

https://www.zacks.com/stock/news/2484468/how-much-upside-is-left-in-intellia-therapeutics-ntla-wall-street-analysts-think-39831

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.

https://www.zacks.com/stock/news/2484223/can-crispr-build-on-casgevys-success-with-its-in-vivo-pipeline

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.

https://www.zacks.com/stock/news/2479598/ntla-stock-down-as-patient-faces-adverse-event-in-gene-therapy-study

Trending Today

Intellia Therapeutics, Inc. Price History

30.04.2025 - NTLA Stock was down 5.8%

• NTLA stock saw a notable decrease following reports of an individual experiencing adverse effects in its gene therapy trial, particularly linked to elevated liver enzymes.
• The downward trend in the stock could be connected to worries regarding the safety and effectiveness of Intellia's gene therapy contender, nex-z, for addressing ATTR-CM.
• Investors might be responding to the possible setbacks in Intellia's phase III trial, causing a loss of faith in the company's future role in the gene therapy industry.
• This incident underscores the risks and fluctuations inherent in biotech stocks, where the outcomes of clinical trials can profoundly influence stock performance.

16.04.2025 - NTLA Stock was up 5.4%

• The FDA approval for Incyte's drug Zynyz in a new cancer indication may have positively influenced the overall sentiment in the biotechnology sector, which includes companies like Intellia Therapeutics.
• Optimistic projections from Wall Street analysts indicating a significant upside in NTLA stock likely played a role in the bullish movement, with investors responding to growth potential.
• Positive industry developments and favorable analyst forecasts may have boosted investor confidence in Intellia Therapeutics, contributing to the strong bullish movement in the stock.

21.03.2025 - NTLA Stock was up 12.6%

• NTLA exhibited strong bullish movement amidst the general market downturn.
• The positive momentum in NTLA may be tied to potential advancements in their CRISPR/Cas9 gene editing therapies.
• Investor optimism regarding NTLA's future outlook likely led to increased buying interest and a rise in the stock price.
• Monitoring any forthcoming announcements or progress from Intellia Therapeutics that could impact the stock's performance is crucial.

13.04.2025 - NTLA Stock was down 6.5%

• Despite reporting a narrower loss than expected in Q1 and surpassing revenue estimates, NTLA experienced a bearish movement.
• Investors might have been expecting even stronger results, leading to a sell-off after the earnings release.
• The market may have reacted negatively to any cautious guidance or concerns raised during the earnings call, overshadowing the positive financial metrics.
• It's possible that profit-taking occurred as some investors locked in gains following the recent stock price increase, despite the positive news about the company's pipeline and financials.

01.04.2025 - NTLA Stock was up 5.7%

• First quarter 2025 financial results and operational successes announced by Intellia Therapeutics potentially exceeded market expectations, leading to increased investor confidence and driving the stock's upward movement.
• Ark Invest, led by Cathie Wood, significantly increased its holdings of Intellia Therapeutics shares, demonstrating strong institutional support and positive sentiment towards the company's future prospects, which in turn, influenced the stock price favorably.
• Growing interest in gene editing technologies and the promise of medical breakthroughs may have attracted more investors to show interest in Intellia Therapeutics, contributing to the bullish market performance of the company.

02.04.2025 - NTLA Stock was up 5.0%

• Despite expectations of a decline in Q1 earnings, Intellia Therapeutics saw a bullish movement, indicating potential positive developments beyond earnings.
• Breaking above the 50-day moving average is a positive technical signal, suggesting increased investor interest and potential upward momentum for NTLA.
• The upcoming conference call to discuss Q1 earnings and company updates may have generated optimism and anticipation among investors, contributing to the bullish movement.
• Significant trades by Ark Invest, including loading up on Intellia Therapeutics shares, could have also boosted investor confidence in the company's future prospects, driving the bullish market movement for NTLA.

21.04.2025 - NTLA Stock was down 5.1%

• The decline in Intellia Therapeutics (NTLA) could be due to investors taking profits following a period of strong performance.
• Investor attention may have shifted to other biotech companies after FDA approval was granted for Zynyz in a new cancer indication for Incyte, prompting a sell-off in NTLA.
• High price targets set by Wall Street analysts, predicting a 408.6% increase in NTLA, might have raised concerns about the stock being overvalued, leading some investors to sell their shares.
• The bearish trend in NTLA appears to stem from a mix of profit-taking, changing investor focus, and potential worries about the stock's valuation based on analyst forecasts.

08.04.2025 - NTLA Stock was up 5.2%

• NTLA experienced a significant bullish trend today, possibly driven by its exceeding revenue expectations by 14.67% in the first quarter.
• Investor sentiment towards NTLA appears positive post the earnings surprise, hinting at growth opportunities and market trust in the company's gene editing treatments.
• The market's reaction suggests that investors are interpreting NTLA's financial performance as a promising sign for its near-term trajectory.

29.04.2025 - NTLA Stock was down 23.7%

• The investigation may have raised concerns among investors about potential legal issues or regulatory challenges for Intellia Therapeutics.
• The uncertainty surrounding the investigation could have led to a loss of confidence in the company's future prospects, resulting in a bearish movement in NTLA stock.
• Investors may be closely monitoring any developments related to the investigation and awaiting further clarity before making investment decisions in Intellia Therapeutics.

16.04.2025 - NTLA Stock was up 6.5%

• Analysts have a positive outlook on NTLA, with a mean price target indicating a potential upside of 408.63%.
• In Q1 2025, Intellia Therapeutics reported a narrower loss than expected and shared encouraging updates on its pipeline candidates, resulting in a surge in its stock price.
• The optimistic analyst forecasts and strong company performance likely contributed to today's bullish movement in NTLA's stock.

05.05.2025 - NTLA Stock was down 5.1%

• Beam Therapeutics' gene-editing therapy for sickle cell disease gaining orphan drug status from the FDA resulted in a surge in BEAM stock.
• Despite Wall Street analysts projecting a potential 398.3% upside for Intellia Therapeutics, the stock still experienced a bearish movement.
• Intellia's stock decline could be linked to a patient in its phase III study encountering adverse events, which impacted the company's gene therapy candidate and investor sentiment.
• The gene-editing sector's competition, notably with CRISPR advancing its in vivo pipeline, contributes to the intricate market dynamics affecting Intellia's stock performance.

30.03.2025 - NTLA Stock was down 5.4%

• A well-known investment firm, managed by Cathie Wood, conducted substantial transactions involving Intellia Therapeutics Inc. (NTLA) and several other companies.
• The activity from this firm, potentially influencing a temporary mismatch between supply and demand for NTLA shares, likely contributed to the stock's decline.
• By selling off holdings in other companies, this firm may have shifted investor attention, adding to the downward pressure experienced by NTLA.
• The current bearish trend in NTLA's stock price could be a response to the evolving investment strategies of prominent investment entities, like the one managed by Cathie Wood.